local_hospital

Prof. MUDr. Jiri Beran CSc. s.r.o.

Address
Tylovo Nabrezi 418/6, 500 02 Hradec Králové, Czechia

Prof. MUDr. Jiri Beran CSc. s.r.o. - Infectious Disease Prevention Research Center

Prof. MUDr. Jiri Beran CSc. s.r.o. is a specialized clinical research facility focused on vaccine development and infectious disease prevention. The center demonstrates particular expertise in conducting Phase III efficacy trials for novel immunization strategies targeting bacterial pathogens in vulnerable adult populations, with emphasis on preventive medicine approaches for community-acquired infections.

  • Vaccine efficacy studies for prevention of invasive bacterial infections
  • Research in extraintestinal pathogenic E. coli (ExPEC) disease prevention
  • Clinical trials in older adults with recurrent urinary tract infections

The center's research portfolio includes pivotal trials evaluating multivalent vaccine candidates designed to prevent life-threatening complications of common bacterial infections. Their work in invasive extraintestinal pathogenic Escherichia coli disease (IED) addresses a critical unmet medical need in older adults who have experienced recurrent urinary tract infections, a population at elevated risk for developing severe invasive infections requiring hospitalization and associated with significant morbidity.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
15
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
2
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 634 other sites in Czechia

description
Trial volume
2
Outperforms 44% of sites
public
Therapeutic diversity
2areas
Outperforms 63% of sites
groups
Sponsor diversity
2sponsors
Outperforms 50% of sites

Therapeutic Area Benchmark — Czechia

Select a therapeutic area to compare against other sites in Czechia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Czechia

Market Share

Country: Czechia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Prof. MUDr. Jiri Beran CSc. s.r.o.

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety Evaluation of MF59-Adjuvanted Influenza Vaccine Versus Non-Adjuvanted Vaccine in Adults Aged 65 and OlderSeqirus UK LimitedPhase IIINot RecruitingOct 2023

IMP list

lock Showing 1 of 15 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)1Unknown2023-10-202023-10-20

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.